Performance of Fetal Cardiac Volume Derived from VOCAL (Virtual Organ Computer-Aided AnaLysis) in Predicting Hemoglobin (Hb) Bart’s Disease

Abstract

Objective: To determine the performance of fetal cardiac volume (CV) in the detection of fetal Hb Bart’s disease among fetuses at risk at 18–22 weeks of gestation and to compare the performance with those of cardiothoracic diameter ratio (CTR) and middle cerebral artery peak systolic velocity (MCA-PSV). Methods: Fetuses at risk of Hb Bart’s disease between 18 and 22 weeks of gestation prospectively underwent echocardiography with acquisition of the volume datasets (VDS) of fetal heart, using 4D-cardiac STIC. Subsequently, off-line analysis was blindly performed to measure cardiac volume using the VOCAL technique. Results: A total of 502 fetuses at risk meeting the inclusion criteria were included in the analysis, consisting of 117 (23.3%) fetuses with Hb Bart’s disease and 385 (76.7%) unaffected fetuses. The mean (±SD) gestational age at the time of ultrasound examination was 19.70 ± 1.3 weeks. In predicting fetal Hb Bart’s disease, CV, using a cut-off Z-score of 1.7, had a sensitivity of 94.9% and specificity of 94.0%. The performance of CV was slightly better than that of CTR but very superior to that of MCA-PSV (areas under curve: 0.988, 0.974 and 0.862, respectively). Conclusions: Fetal CV has a very high performance in predicting fetal Hb Bart’s disease at mid-pregnancy, comparable with CTR and much better than MCA-PSV.